方盛製藥(603998.SH):擬與關聯方新元產投共設融大藥業
格隆匯3月6日丨方盛製藥(603998.SH)公佈,公司擬與關聯方湖南方盛新元健康產業投資有限公司(“新元產投”)共同發起設立廣東方盛融大藥業有限公司(以登記機關核准登記的結果為準,“融大藥業”),註冊資本2000萬元,公司以自有資金出資1100萬元,佔比55%。
公司設立控股子公司融大藥業,是在藥品上市許可持有人制度基礎上,藉助註冊所在地的人才、政策等優勢開展中成藥研發業務,是公司打造以創新中藥為核心的健康產業集團的戰略發展需要。此次設立子公司有利於公司不斷推進工商聯盟平台的建設,持續提升公司中藥研發能力;此外,設立合資公司有利於合理降低公司因對外投資及培育新產業可能存在的風險,充分發揮各方的優勢,實現多方共贏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.